![Peiqi Sun](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenance du réseau au premier degré de Peiqi Sun
Entité | Type d'entité | Industrie | |
---|---|---|---|
Silicon INSITE, Inc.
![]() Silicon INSITE, Inc. BiotechnologyHealth Technology Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.
8
| Subsidiary | Biotechnology | 8 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Peiqi Sun via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
INDAPTUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Beth Israel Deaconess Medical Center, Inc.
![]() Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Director/Board Member | |
Acepodia Biotechnologies, Ltd.
![]() Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Harbour BioMed (Shanghai) Co., Ltd.
![]() Harbour BioMed (Shanghai) Co., Ltd. BiotechnologyHealth Technology Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China. | Biotechnology | Chief Executive Officer | |
JW (CAYMAN) THERAPEUTICS CO. LTD | Biotechnology | Chief Tech/Sci/R&D Officer | |
JW Therapeutics (Shanghai) Co., Ltd.
![]() JW Therapeutics (Shanghai) Co., Ltd. BiotechnologyHealth Technology JW Therapeutics (Shanghai) Co., Ltd. engages in biopharmaceutical industry. It focuses on the development, transformation, and promotion of cell-based immunotherapies to treat cancer. The company was founded by Yi Ping Li on February 18, 2016 and is headquartered in Shanghai, China. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Inceptor Bio LLC
![]() Inceptor Bio LLC BiotechnologyHealth Technology Inceptor Bio LLC operates as a biotechnology industry company. The company is headquartered in Raleigh, NC. | Biotechnology | Director/Board Member | |
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Biotechnology | Chief Tech/Sci/R&D Officer | |
Berlex Pharmaceuticals, Inc. | Corporate Officer/Principal | ||
China Pharmaceutical University | College/University | Doctorate Degree | |
Bayer HealthCare Pharmaceuticals, Inc.
![]() Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Iowa Carver College of Medicine | College/University | Doctorate Degree | |
University of Iowa | College/University | Undergraduate Degree | |
JUNO THERAPEUTICS INC | Biotechnology | Chief Tech/Sci/R&D Officer | |
FRONTAGE HOLDINGS CORPORATION | Biotechnology | Director/Board Member | |
Jilin University | College/University | Graduate Degree | |
HBM HOLDINGS LIMITED | Pharmaceuticals: Other | Chief Executive Officer | |
Refuge Biotechnologies, Inc.
![]() Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Shenzhen Jingtai Technology Co., Ltd.
![]() Shenzhen Jingtai Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015. | Miscellaneous Commercial Services | Director/Board Member | |
STRUCTURE THERAPEUTICS INC. | Miscellaneous Commercial Services | Director/Board Member | |
Wuhan Neurophth Biotechnology Co., Ltd.
![]() Wuhan Neurophth Biotechnology Co., Ltd. BiotechnologyHealth Technology Wuhan Neurophth Biotechnology Co., Ltd. is a leading in-vivo gene therapy company for ophthalmic diseases based in Wuhan, China. The Chinese company's core product, nr082 (nfs-01), is designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) and has been granted orphan drug designation (ODD) by the FDA and EMA. It is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by the Chinese National Medical Products Administration (NMPA) and the FDA. The company's pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy, and other preclinical candidates. The company was founded in 2016 by Bin Li, Su Xiao, Dabo Cai, and Bin Li has been the CEO since then. | Biotechnology | Director/Board Member | |
Shanghai Jiao Tong University | College/University | Undergraduate Degree | |
Taizhou EOC Pharma Co., Ltd.
![]() Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Pharmaceuticals: Major | Director/Board Member | |
NuProbe USA, Inc.
![]() NuProbe USA, Inc. Miscellaneous Commercial ServicesCommercial Services NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Hongshan
![]() Hongshan Investment ManagersFinance Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong. | Investment Managers | Private Equity Investor | |
Silicon Therapeutics, Inc. | Chairman | ||
Insilico Medicine Cayman TopCo
![]() Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Miscellaneous Commercial Services | Director/Board Member | |
Sanofi (China) Investment Co. Ltd. | Corporate Officer/Principal | ||
XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD | Miscellaneous Commercial Services | Director/Board Member | |
Hbm Guangzhou | Chief Executive Officer | ||
Hbm Suzhou Co. Ltd. | Chief Executive Officer | ||
Xuzhou Medical University | College/University | Graduate Degree | |
Aprinoia Therapeutics, Inc. /US/
![]() Aprinoia Therapeutics, Inc. /US/ BiotechnologyHealth Technology Aprinoia Therapeutics, Inc. operates as a global clinical-stage biopharmaceutical company. It develops imaging diagnostic tools, targeted therapy drugs, and other products. The company was founded in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
ENLIVEX THERAPEUTICS LTD. | Biotechnology | Director/Board Member | |
Verimmune, Inc.
![]() Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | Biotechnology | Director/Board Member | |
EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Shionogi Bioresearch Corp. | Corporate Officer/Principal | ||
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED | Pharmaceuticals: Major | Director/Board Member | |
Harvard Medical School | College/University | Corporate Officer/Principal | |
Georgetown University | College/University | Graduate Degree | |
CommonHealth
![]() CommonHealth Advertising/Marketing ServicesCommercial Services CommonHealth provides marketing and advertising services to the healthcare industry. Its services include market research, advertising, strategic planning and media planning. The company represents both domestic and global brands of leading healthcare manufacturers and marketers. CommonHealth was founded in 1974 and is headquartered in Parsippany, NJ. | Advertising/Marketing Services | Comptroller/Controller/Auditor | |
Stony Brook University | College/University | Doctorate Degree | |
MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
SERES THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
The Johns Hopkins University | College/University | Undergraduate Degree | |
The Johns Hopkins University School of Medicine | College/University | Doctorate Degree | |
CONTRAFECT CORPORATION | Biotechnology | Chief Executive Officer | |
Janssen R&D Ireland Ltd. | President |
Statistiques
Internationale
Etats-Unis | 28 |
Chine | 17 |
Îles Cayman | 3 |
Taïwan | 2 |
Allemagne | 2 |
Sectorielle
Health Technology | 24 |
Consumer Services | 12 |
Commercial Services | 8 |
Health Services | 2 |
Finance | 2 |
Opérationnelle
Director/Board Member | 30 |
Corporate Officer/Principal | 15 |
Independent Dir/Board Member | 13 |
Chairman | 13 |
Chief Executive Officer | 7 |
Relations les plus connectées
Insiders | |
---|---|
Roger Pomerantz | 30 |
Mark Gilbert | 13 |
Jing Song Wang | 12 |
Cui Ping Gu | 10 |
Lijun Sun | 8 |
Christopher Borella | 3 |
Elliot L. Chaikof | 2 |
Finith Jernigan | 1 |